FOLH1 and xerostomia: The observed growth of control tumors suggests that PSMA-1-DOTA, when labeled with therapeutic radionuclides, can effectively kill cancer cells, and could be a viable candidate for treatment trials, particularly for patients who experience severe xerostomia from current PSMA-targeted RLTs.